For Immediate Release
July 20, 2015

Mary Kuramoto
513-579-9911 x 2523

CINCINNATI, OH — (July 20, 2015) – Medpace, a global drug and medical device Clinical Research Organization (CRO), announced that Phillippa J. Miranda MD has joined Medpace as Sr. Director, Medical Affairs. Dr. Miranda has 15 years of professional medical experience including extensive clinical research work as a medical monitor in the area of diabetes and endocrinology. Medpace – known for its full-service approach to Phase I-IV clinical development as well as its strong regulatory expertise – welcomes Dr. Miranda to a team of physicians at Medpace. The company’s unique physician-driven model provides specialized expertise throughout the design and management of a Sponsor’s study or program, which results in a distinct advantage through a greater depth of knowledge and hands-on leadership.

About Phillippa J. Miranda, MD

Dr. Miranda is board certified in Endocrinology, Diabetes, and Metabolism. Her therapeutic expertise covers a wide range of metabolic indications with significant medical monitoring experience in the areas of type 2 diabetes, type 1 diabetes, and obesity. Dr. Miranda has over 7 years of experience conducting clinical research studies with a large CRO and is well versed in the conduct of Phase 2 and 3 studies in endocrinology. Dr. Miranda received her B.S. in Biology with a B.A. in Chemistry from Duke University. She received her M.D. from Duke University School of Medicine and completed her residency in Internal Medicine and her fellowship in Endocrinology at Duke. She served on the faculty in the Division of Endocrinology at Duke University Health System for 5 years prior to transitioning to industry.


Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions – the US, Europe, Central, and Eastern Europe, India, Asia Pacific, and China. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information visit the Medpace website at